Capsules: Clinical Trials

57 trials of Capsules, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

36 completed, 7 unknown, 4 recruiting, 3 not yet recruiting. 57 Phase 1, 14 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 157Completed 36, Unknown 7, Recruiting 4, Not yet recruiting 3, Terminated 3, Active not recruiting 2, Withdrawn 2
Phase 214Completed 5, Not yet recruiting 2, Recruiting 2, Terminated 2, Unknown 2, Active not recruiting 1

Follow Capsules: new trials by email Literature Review of Capsules trials Research Report on Capsules

Trials (filtered) newest first · largest first

All 57 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response
Lithium orotate, Matched Placebo (Capsules) - Alzheimer s Disease
Phase 1 / Phase 2Not yet recruitingJohns Hopkins University402026-12-012026-10-07
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
ATV-1601, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Phase 1 / Phase 2RecruitingAtavistik Bio, Inc1002026-07-272026-11-06
Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions
SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules - Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP)
Phase 1Active not recruitingOscotec Inc.482026-07-102026-09-01
Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled Trial
Fecal Microbiota Transplantation (FMT) Capsules, Placebo capsules - Heart Failure With Preserved Ejection Fraction (HFPEF), Chronic Heart Failure
Phase 1 / Phase 2Not yet recruitingThe First Affiliated Hospital of Air Force Medicial University502026-06-012026-06-05
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.
Ingavirin forte, capsules, 90 mg + 20 mg, Ingavirin, capsules, 90 mg - Influenza, Acute Respiratory Viral Infections
Phase 1RecruitingValenta Pharm JSC362025-07-112026-06-12
Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients
EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd. - Pruritus
Phase 1Not yet recruitingRabin Medical Center302025-05-302025-04-17
L-Citrulline and Endothelial Function
L-Citrulline, capsule - Aging
Phase 1CompletedUniversity of Oklahoma202024-01-032026-03-12
A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants
GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo - Healthy Volunteers
Phase 1UnknownGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics702023-10-022024-02-15
A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
LTI-03, Placebo - Idiopathic Pulmonary Fibrosis
Phase 1CompletedRein Therapeutics242023-07-062025-07-31
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
LQT-1213, Placebo, Dofetilide 250 μg Cap - Long QT Syndrome
Phase 1 / Phase 2TerminatedThryv Therapeutics, Inc.422023-03-122025-07-24
Effect of Supplementation With Anthocyanins on Iron Metabolism in Female Swimmers
Black chokeberry extract in capsules with 18% standardization of the anthocyanins content, Chokeberry fiber in capsules - Iron Deficiencies, Inflammation
Phase 1 / Phase 2CompletedPoznan University of Physical Education222023-03-012024-07-03
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
Intestinal Microbiota Transplant (IMT) Capsules, Placebo Capsules - Liver Disease; Alcohol-Related, Cirrhosis
Phase 1 / Phase 2Active not recruitingVirginia Commonwealth University802022-11-212026-08-24
Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
Nabilone - Intellectual Disability, Developmental Disability
Phase 1CompletedHsiang-Yuan Lin202022-03-172026-01-23
The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions
Aviga, capsules 50 mg / Sutent®, capsules 50 mg, Sutent®, capsules 50 mg / Aviga, capsules 50 mg - Bioequivalence
Phase 1UnknownJLLC NatiVita222022-01-212022-02-01
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
Veliparib, capsule, Veliparib, tablet, Carboplatin - Cancer - Ovarian
Phase 1WithdrawnAbbVie2021-11-152021-12-08
Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects.
Dexlansoprazole - Healthy, Bioequivalence Study
Phase 1CompletedUniversity of Karachi602021-09-182023-11-29
A Study to Investigate the Effect of Food on the Pharmacokinetics of IN-A002 Capsule in Healthy Male Subjects
IN-A002(IN-115314) capsule - Healthy
Phase 1UnknownHK inno.N Corporation122021-08-132021-08-25
Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim
Placebo (Lactose) Capsule, 0.75 mg Alprazolam Capsule, Cannabis (6.18% THC / <0.025% CBD) - Driving Behavior, Driving Under the Influence
Phase 1CompletedTimothy L. Brown132021-07-162023-07-25
3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
EXS21546 Powder for Oral Suspension, EXS21546 Granule in Capsule, Midazolam - Oncology
Phase 1CompletedExscientia AI Limited642020-12-082022-05-16
Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.
Low dose tadalafil 5 mg, Tolterodine 4 Mg Oral Capsule, Extended Release, Placebo - Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence
Phase 1CompletedKasr El Aini Hospital902020-12-012022-08-15

Showing 20 of 57. Sign in to see all of them.

Conditions studied

Neoplasms (3)  ·  Inflammation (2)  ·  Substance-Related Disorders (2)  ·  Aggression (1)  ·  Alcoholism (1)  ·  Arteriovenous Malformations (1)  ·  Arthritis, Rheumatoid (1)  ·  Asthma (1)  ·  Attention Deficit Disorder with Hyperactivity (1)  ·  Autoimmune Diseases (1)  ·  Bacterial Infections (1)  ·  COVID-19 (1)  ·  Cardiomyopathy, Hypertrophic (1)  ·  Cardiovascular Diseases (1)  ·  Colonic Neoplasms (1)

Sponsors

Actavis Inc. (4)  ·  AstraZeneca (2)  ·  Genentech, Inc. (2)  ·  Mylan Pharmaceuticals Inc (2)  ·  AbbVie (1)  ·  Ahmed A. H. Abdellatif (1)  ·  Andrew Slivka (1)  ·  Atavistik Bio, Inc (1)  ·  Boehringer Ingelheim (1)  ·  Cingulate Therapeutics (1)  ·  Cytokinetics (1)  ·  Daiichi Sankyo (1)  ·  Debiopharm International SA (1)  ·  Dwight Koeberl, M.D., Ph.D. (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)

Countries

United States (28)  ·  United Kingdom (6)  ·  South Korea (5)  ·  Canada (4)  ·  China (3)  ·  Australia (2)  ·  Belgium (2)  ·  Egypt (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Pakistan (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Argentina (1)

Top investigators

Daniel V. Freeland, DO (2)  ·  Gaetano Morelli, M.D. (2)  ·  James P. Doherty, DO (2)  ·  Andriy Yabluchanskiy, MD, PhD (1)  ·  Christopher Morrow, MD, MHS (1)  ·  Dwight D Koeberl, MD, PhD (1)  ·  Erik Brouwer, MD (1)  ·  Frederick Wittke, MD (1)  ·  Grant Bochicchio, MD, MPH (1)

Results publications

PMID 25467588, PMID 27032509, PMID 29881409, PMID 30025991, PMID 30869182, PMID 30937899, PMID 31740368, PMID 32863171, PMID 33568226, PMID 34471960, PMID 34814185, PMID 35045888, PMID 35127778, PMID 36061336, PMID 39929221, PMID 42518155, PMID 42538332

NIH funding

2018 (2), 2015 (1), 2023 (1), R01AA029398 (1), R21AT002073 (1), ZIAHD000641-23 (1)